Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$11.35
-8.5%		$7.92
$2.74
▼
$12.58
$3.48B1.210.41 million shs5.84 million shs
Annexon, Inc. stock logo
ANNX
Annexon
$4.97
-5.3%		$5.41
$2.03
▼
$7.18
$942.21M1.182.60 million shs1.62 million shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$8.01
-3.0%		$5.47
$1.76
▼
$9.36
$3.63B0.7120.22 million shs7.68 million shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$11.29
-0.8%		$11.12
$6.28
▼
$12.48
$3.84B-0.24128,270 shs88,468 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
0.00%+0.27%+99.02%+83.95%+160.92%
Annexon, Inc. stock logo
ANNX
Annexon
0.00%-1.97%-5.69%-8.30%+135.55%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%-3.38%+70.79%+95.37%+230.99%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%-0.35%+12.23%+19.72%-6.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$11.35
-8.5%		$7.92
$2.74
▼
$12.58
$3.48B1.210.41 million shs5.84 million shs
Annexon, Inc. stock logo
ANNX
Annexon
$4.97
-5.3%		$5.41
$2.03
▼
$7.18
$942.21M1.182.60 million shs1.62 million shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$8.01
-3.0%		$5.47
$1.76
▼
$9.36
$3.63B0.7120.22 million shs7.68 million shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$11.29
-0.8%		$11.12
$6.28
▼
$12.48
$3.84B-0.24128,270 shs88,468 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
0.00%+0.27%+99.02%+83.95%+160.92%
Annexon, Inc. stock logo
ANNX
Annexon
0.00%-1.97%-5.69%-8.30%+135.55%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%-3.38%+70.79%+95.37%+230.99%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%-0.35%+12.23%+19.72%-6.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.71
Moderate Buy$12.8313.07% Upside
Annexon, Inc. stock logo
ANNX
Annexon
2.33
Hold$15.33208.52% Upside
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.45
Hold$8.8910.97% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
2.86
Moderate Buy$20.4080.69% Upside

Current Analyst Ratings Breakdown

Latest ANNX, TLX, ABCL, and IOVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$7.00 ➝ $10.00
8/21/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Hold (C-)
8/20/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$4.00 ➝ $7.00
8/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$22.00
8/18/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$10.00 ➝ $11.00
8/13/2026
Annexon, Inc. stock logo
ANNX
Annexon
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform
8/11/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$12.00 ➝ $30.00
8/7/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$6.00
8/7/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/7/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$11.00 ➝ $13.00
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$75.13M46.32N/AN/A$2.92 per share3.89
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$0.98 per shareN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$263.50M13.77N/AN/A$1.62 per share4.94
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M4.77$0.04 per share267.77$1.44 per share7.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.41M-$0.54N/AN/AN/A-248.83%-17.49%-12.36%11/5/2026 (Estimated)
Annexon, Inc. stock logo
ANNX
Annexon
-$206.69M-$1.16N/AN/AN/AN/A-106.15%-79.82%11/9/2026 (Estimated)
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$390.98M-$0.73N/AN/AN/A-89.11%-40.51%-31.65%11/5/2026 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A188.17N/AN/AN/AN/AN/A

Latest ANNX, TLX, ABCL, and IOVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.2388-$0.28-$0.0412-$0.28$6.50 millionN/A
8/6/2026Q2 2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.1335-$0.11+$0.0235-$0.11$87.83 million$198.63 million
8/5/2026Q2 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.1640-$0.18-$0.0160-$0.18$7.85 million$4.05 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
12.77
12.77
Annexon, Inc. stock logo
ANNX
Annexon
N/A
5.53
5.53
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
4.34
3.82
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.16
2.01
1.85

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Annexon, Inc. stock logo
ANNX
Annexon
N/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.40%
Annexon, Inc. stock logo
ANNX
Annexon
10.31%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
7.80%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500306.61 million219.53 millionOptionable
Annexon, Inc. stock logo
ANNX
Annexon
60189.58 million170.03 millionOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
500452.97 million417.64 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,184339.78 millionN/AN/A

Recent News About These Companies

Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Down 4.5% - Time to Sell?
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-stock-price-down-45-time-to-sell-2026-08-26/
Telix Pharmaceuticals: Execution Is The Name Of The Game Here
August 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4939766-telix-pharmaceuticals-execution-is-the-name-of-the-game-here
Wedbush Reaffirms "Outperform" Rating for Telix Pharmaceuticals (NASDAQ:TLX)
August 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975586
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-shares-gap-down-heres-what-happened-2026-08-21/
HotCopper highlights: Zip dominates investor attention as Telix, Liontown and American Tungsten trend
August 21, 2026  |  msn.comhttps://www.msn.com/en-au/money/top-stocks/hotcopper-highlights-zip-dominates-investor-attention-as-telix-liontown-and-american-tungsten-trend/ar-AA2aC3f9
Why were Telix shares just downgraded?
August 20, 2026  |  fool.com.auhttps://www.fool.com.au/2026/08/21/why-were-telix-shares-just-downgraded/
Telix Pharmaceuticals Limited (TLX) Stock: EBITDA Surges 146% as Revenue Hits $477M 
August 20, 2026  |  blockonomi.comhttps://blockonomi.com/telix-pharmaceuticals-limited-tlx-stock-ebitda-surges-146-as-revenue-hits-477m/
Telix Pharmaceuticals Limited: Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
August 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69361480-telix-pharmaceuticals-limited-telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline-399.htm
Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from Wedbush
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-receives-outperform-rating-from-wedbush-2026-08-20/
Telix Pharmaceuticals (NASDAQ:TLX) Announces Earnings Results
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-announces-earnings-results-2026-08-20/
Telix half-year revenue increases 22 per cent to 477 million dollars
August 20, 2026  |  vir.com.vnV
Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
August 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4938549-telix-pharmaceuticals-limited-tlx-q2-2026-earnings-call-transcript
Telix Pharmaceuticals Limited 2026 Q2 - Results - Earnings Call Presentation
August 19, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4938545-telix-pharmaceuticals-limited-2026-q2-results-earnings-call-presentation
Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress
August 19, 2026  |  msn.comhttps://www.msn.com/en-au/money/general/telix-pharmaceuticals-delivers-robust-half-year-earnings-and-pipeline-progress/ar-AA2avMqF
Telix Pharmaceuticals H1 Earnings Call Highlights
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-h1-earnings-call-highlights-2026-08-19/
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
August 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348062/0/en/telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline.html
Telix Pharmaceuticals (NASDAQ:TLX) Trading Down 4.3% - Should You Sell?
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-trading-down-43-should-you-sell-2026-08-14/
Telix Pharmaceuticals (TLX) to Release Quarterly Earnings on Thursday
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-tlx-to-release-quarterly-earnings-on-thursday-2026-08-13/
Telix Pharmaceuticals Ltd. ADR
August 12, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/tlx/financials/income/quarter
Hennion & Walsh Asset Management Inc. Takes Position in Telix Pharmaceuticals Limited $TLX
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hennion-walsh-asset-management-inc-takes-position-in-telix-pharmaceuticals-limited-tlx-2026-08-12/
Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-limited-nasdaqtlx-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-08-09/

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$11.35 -1.05 (-8.47%)
As of 08/28/2026 04:00 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Annexon stock logo

Annexon NASDAQ:ANNX

$4.97 -0.28 (-5.33%)
As of 08/28/2026 04:00 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$8.01 -0.25 (-3.03%)
As of 08/28/2026 04:00 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$11.29 -0.09 (-0.79%)
As of 08/28/2026 04:00 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas